Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

CLL: Evolution of Treatment

July 13th 2021

William Wierda, MD, PhD, leads a panel of experts in a discussion pertaining to the treatment of chronic lymphocytic leukemia (CLL), beginning with the evolving treatment landscape.

Frontline Ibrutinib/Venetoclax Elicits Durable Responses in CLL With Undetectable MRD

July 13th 2021

Fixed-duration ibrutinib plus venetoclax produced superior progression-free survival when compared with chlorambucil plus obinutuzumab in the frontline treatment of patients with chronic lymphocytic leukemia, with durable responses observed in those who achieved undetectable minimal residual disease negativity.

Dr. Grunwald on the Clinical Implications of Tisagenlecleucel in B-ALL Treatment

July 12th 2021

Michael R. Grunwald, MD, FACP, discusses the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.

Dr. Abedin on the Safety and Efficacy of Ibrutinib in CLL

July 6th 2021

Sameem Abedin, MD, discusses the safety and efficacy of ibrutinib in the treatment of patients with chronic lymphocytic leukemia.

Long-Term Data Showcase the Clinical Utility of Fixed-Duration Venetoclax/Obinutuzumab in Treatment-Naïve CLL

July 6th 2021

Fixed-duration venetoclax plus obinutuzumab demonstrated prolonged remissions compared with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukemia and comorbidities.

Dr. Ailawadhi on Next Steps With Lisaftoclax in CLL

June 30th 2021

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia.

Dr. Byrd on Future Directions With Acalabrutinib in CLL

June 30th 2021

John C. Byrd, MD, discusses future directions with acalabrutinib in chronic lymphocytic leukemia.

Dr. Barr on the Rationale for the Long-Term Evaluation of the RESONATE-2 Trial in CLL

June 30th 2021

Paul M. Barr, MD, discusses the rationale for the long-term analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Ghia on the Rationale for the CAPTIVATE Trial in CLL

June 29th 2021

Paolo Ghia, MD, PhD, discusses the rationale for the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Ailawadhi on the Safety Profile of Lisaftoclax in CLL

June 25th 2021

Sikander Ailawadhi, MD, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia.

Dr. Abedin on Managing Cardiac Toxicities With Acalabrutinib vs Ibrutinib in CLL

June 22nd 2021

Sameem Abedin, MD, discusses managing cardiac toxicities with acalabrutinib vs ibrutinib in patients with chronic lymphocytic leukemia.

Dr. Abedin on Frontline Treatment Considerations in CLL 

June 21st 2021

Sameem Abedin, MD, discusses frontline treatment considerations for patients with chronic lymphocytic leukemia.

Pirtobrutinib Elicits Encouraging Efficacy in CLL, SLL, MCL, & Other Non-Hodgkin Lymphomas

June 21st 2021

Pirtobrutinib produced promising efficacy in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma, those with mantle cell lymphoma and other non-Hodgkin lymphomas, and those who progressed on Richter transformation–directed therapy.

Dr. Abedin on the Clinical Significance of Undetectable MRD in CLL

June 21st 2021

Sameem Abedin, MD, discusses the clinical significance of undetectable minimal residual disease status in chronic lymphocytic leukemia.

Dr. Siddiqi on the Role of Acalabrutinib in Frontline CLL

June 16th 2021

Tanya Siddiqi, MD, discusses the role of acalabrutinib as a frontline treatment for patients with chronic lymphocytic leukemia.

Dr. Byrd on the Clinical Implications of the ELEVATE-RR Trial in CLL

June 16th 2021

John C. Byrd, MD, discusses the clinical implications of the phase 3 ELEVATE-RR trial in chronic lymphocytic leukemia.

An Expert Provides Insight Into the Use of BTK Inhibitors in CLL

June 15th 2021

Parameswaran Venugopal, MD, discussed the toxicity profiles of BTK inhibitors regarding treatment selection in CLL.

Frontline Ibrutinib/Venetoclax Yields Superior Outcomes Vs Chlorambucil/Obinutuzumab in CLL

June 12th 2021

Fixed-duration ibrutinib and venetoclax as a first-line treatment yielded superior progression-free survival compared with chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia.

Dr. Ghia on the Efficacy of Ibrutinib/Venetoclax in CLL

June 12th 2021

Paolo Ghia, MD, PhD, discusses results seen with the combination of ibrutinib and venetoclax as a first-line treatment for patients with chronic lymphocytic leukemia.

Hillmen Highlights Acalabrutinib’s Tolerability Vs Ibrutinib in Previously Treated CLL

June 12th 2021

The next-generation, selective BTK inhibitor acalabrutinib demonstrated noninferiority to ibrutinib in terms of progression-free survival in patients with previously treated chronic lymphocytic leukemia in the phase 3 ELEVATE-RR trial.